THE NEXT GENERATION HEART VALVE

Inspired by Nature, Engineered for Life

A Critical Unmet Need

Patients with advanced valvular heart disease, including aortic stenosis and rheumatic heart disease, face a critical and unresolved clinical challenge. Existing treatment options, while life- saving, are inherently limited. Bioprosthetic valves derived from animal tissue are prone to structural deterioration over time, frequently necessitating repeat interventions that carry increased procedural risk. Mechanical valves offer durability but require lifelong anticoagulation, introducing ongoing management burden and bleeding risk.

There remains a significant unmet need for a valve solution that restores physiological function while providing durable long-term performance without compromising patient safety or quality of life.

Tony's story: From a school trek to lifesaving heart valve surgery

“My heart valve replacement has given me a new lease on life, and I am truly thankful. However, my current treatment means I must take warfarin every day, even though the valve itself is permanent. How life changing it would be to have a new heart valve that mimics the natural function of a healthy human valve, without the need for potent medications for the rest of my life.”

A New Approach to Valve Replacement

CoraMetix is advancing a new approach to heart valve replacement through a class of bioinspired valves engineered from specialised polymers and manufactured using advanced three-dimensional printing. Grounded in a detailed understanding of the structure and function of healthy valve tissue, our patented design is intended to restore natural haemodynamic performance while delivering enhanced durability and long-term reliability compared with existing valve technologies.

In parallel, our manufacturing approach has the potential to reduce production complexity and cost relative to valves derived from animal tissue. It also enables precise patient specific customisation, allowing each device to be tailored to the unique anatomical requirements of the individual.

Healthy Heart Valve Natural Collagen Microstructure

CoraMetix Bio-inspired 3D Printed Valve Microstructure

Enabling Technology

CoraMetix’s valve platform is enabled by Melt Electrowriting, an advanced microscale three-dimensional printing technology that allows precise control over fibre architecture beyond the limits of conventional manufacturing approaches. This capability enables the creation of highly organised structures designed to replicate the mechanical and functional properties of native valve tissue.

Our Melt Electrowriting platform is being developed for automated high throughput production, with a clear pathway to scalable and cost-efficient manufacturing at clinical volumes. This approach supports the consistent fabrication of complex valve geometries while maintaining precision and reproducibility.

All systems are designed and built in house in Western Australia, enabling rapid iteration, continuous optimisation, and close integration between materials development, engineering, and manufacturing. By combining advanced materials, precision engineering, and proprietary production technologies, CoraMetix is redefining how cardiovascular implants are designed, manufactured, and translated to clinical use.

Looking Ahead

CoraMetix is progressing toward the next phase of development, focused on advancing its valve platform toward clinical readiness and long-term impact. The company is expanding its multidisciplinary team, with planned growth in commercial leadership and governance to support translation, partnerships, and market entry.

On the product pathway, development is focused on refining and validating the valve design toward a defined design freeze, laying the foundation for regulatory progression and first in human studies. Over time, this will support carefully staged clinical evaluation to demonstrate safety and performance in patients.

In parallel, CoraMetix is continuing to scale and mature its manufacturing capability, with a focus on automation, reproducibility, and cost-efficient production at clinical volumes. This includes further development of its Melt Electrowriting platform to enable consistent, high precision fabrication at scale.

Together, these efforts position CoraMetix to transition from advanced development to clinical application, with the goal of delivering a new generation of heart valve solutions that improve patient outcomes and expand access to effective treatment globally.